Drugs / HDM1002
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT07594847 | Mar → Sep 2026 overdue | — | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07331389 | Sep 2025 → Jan 2026 overdue | — | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06985615 | Mar 2025 → Jan 2026 overdue | — | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06608329 | Oct → Nov 2024 overdue | — | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06601517 | Oct 2024 → Feb 2025 overdue | — | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06576401 | Aug → Oct 2024 overdue | — | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06562088 | Aug → Nov 2024 overdue | — | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06500299 | Jul → Oct 2024 | — | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT06481085 | Jun 2024 → May 2025 | type 2 diabetes mellitus | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07193459 | Aug 2025 → Oct 2026 expected | type 2 diabetes mellitus | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07082114 | Jul 2025 → Feb 2027 expected | type 2 diabetes mellitus | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06885021 | Mar 2025 → May 2026 overdue | — | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06520540 Comparator | Jul → Nov 2024 overdue | — | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HDM1002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06500299 ↗ |
| Route | Oral | “administered orally once daily” NCT06481085 ↗ |